ASH® 2025 Highlights: Presenter Vignette – Maria Victoria Mateos Manteca
Maria Victoria Mateos Manteca
MD, PhD
University of Salamanca
LBA 6
Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3.
This program has been made possible through unrestricted support from Astellas, Daiichi Sankyo, Eli Lilly and Merck.